StageZero Life Sciences (TSX:SZLS) Total Liabilities : C$12.97 Mil (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Total Liabilities?

StageZero Life Sciences's Total Liabilities for the quarter that ended in Sep. 2023 was C$12.97 Mil.

StageZero Life Sciences's quarterly Total Liabilities declined from Mar. 2023 (C$13.22 Mil) to Jun. 2023 (C$12.22 Mil) but then increased from Jun. 2023 (C$12.22 Mil) to Sep. 2023 (C$12.97 Mil).

StageZero Life Sciences's annual Total Liabilities declined from Dec. 2020 (C$12.48 Mil) to Dec. 2021 (C$10.09 Mil) but then increased from Dec. 2021 (C$10.09 Mil) to Dec. 2022 (C$11.15 Mil).

StageZero Life Sciences Total Liabilities Historical Data

The historical data trend for StageZero Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Total Liabilities Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

9.35

8.50

12.48

10.09

11.15

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															9.29	11.15	13.22	12.22	12.97

StageZero Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

StageZero Life Sciences's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.545	+	(0.782	+	0.818
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.15

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	0.952	-	-10.193
	=	11.15

StageZero Life Sciences's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.19	+	(1.003	+	0.774
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.97

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	0.687	-	-12.279
	=	12.97

StageZero Life Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines